IR

Ingersoll Rand Inc. (IR) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Ingersoll Rand Inc. is a global provider of mission-critical flow creation products and industrial/life science solutions, operating through two segments: Industrial Technologies and Services and Precision and Science Technologies. The company reported a net loss for the quarter, primarily driven by significant non-cash impairment charges and an equity method investment loss, despite revenue growth driven by acquisitions and pricing.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2025 revenue increased 4.6% year-over-year, driven by acquisitions ($116.4M), higher pricing ($33.1M), and favorable foreign currency ($27.8M), partially offset by lower organic volumes ($94.7M).
• Impairment Charges: The company recognized a non-cash goodwill impairment of $229.7 million and other intangible asset impairment of $36.1 million in Q2 2025. These charges were concentrated in the Precision and Science Technologies segment (Biopharma and Aerospace & Defense reporting units) due to increased discount rates, market multiple contraction, and reduced forecasts for a significant customer.
• Equity Method Investment Loss: A $120.9 million impairment charge was recognized on the company's 45% equity interest in the legacy High Pressure Solutions (HPS) business, reducing its carrying value to zero.
• Operating Expenses: "Other operating expense, net" decreased significantly to $19.9M from $88.2M in Q2 2024, primarily due to the absence of a $58.8M loss on asbestos sale recorded in the prior year.
• Segment Performance:
  • Industrial Technologies and Services: Revenue up 1.7%; Adjusted EBITDA down 2.1% due to lower organic volumes and unfavorable cost productivity.
  • Precision and Science Technologies: Revenue up 17.0%; Adjusted EBITDA up 14.0%, driven by acquisitions and pricing, despite lower organic volumes.

Guidance, Outlook, and Risks

Management Commentary: Management highlighted that while GAAP net income was negatively impacted by non-cash impairments, underlying operational performance remained resilient with Adjusted EBITDA growing 3.0% year-over-year. The company continues to execute business transformation initiatives and monitor macroeconomic conditions, including inflation, interest rates, and geopolitical instability.

Subsequent Event: On July 1, 2025, the company completed the acquisition of Termomeccanica Industrial Compressors S.p.A. (TMIC) and Adicomp S.p.A. for approximately €160 million.

Risks and Contingencies:

• Macroeconomic Factors: Exposure to global economic instability, trade policy shifts (tariffs), and geopolitical conflicts.
• Intangible Assets: A significant portion of assets consists of goodwill and intangibles, which remain subject to impairment risk if market conditions or forecasts deteriorate further.
• Debt Service: The company carries significant debt ($4.8B) with interest rates averaging ~5.0%. Liquidity is supported by $2.6B in unused revolver capacity and commercial paper availability.
• Equity Investment: The HPS investment is now fully impaired; future value recovery is uncertain.

Investor Verification Checklist

• Impairment Drivers: Verify the specific assumptions used for the Biopharma and Aerospace & Defense goodwill impairments (discount rates, market multiples, customer forecasts) to assess if these are temporary or indicative of a structural decline.
• Organic Volume Trends: Monitor the continued decline in organic volumes (-5.4% in Q2) across both segments to determine if pricing power can sustain revenue growth.
• Debt Covenants: Confirm ongoing compliance with the 3.50x net debt-to-EBITDA leverage ratio covenant under the Revolving Credit Facility, especially given the recent acquisition activity.
• Acquisition Integration: Assess the integration progress and synergy realization of the 2024 ILC Dover acquisition and 2025 smaller acquisitions.
• Equity Method Investment: Review the status of the HPS investment to understand if any residual value or future cash flows remain, given the full impairment write-down.